DSM and Svelte Medical Systems enter into license and supply agreement

DSM, and Svelte® Medical Systems, Inc., a privately held company developing next generation endovascular therapies, today announced they have entered into a license and supply agreement granting Svelte the right to use DSM’s proprietary bioerodible amino acid based drug carrier in the design of their All In One non-thrombogenic, non-inflammatory drug-eluting stent system.

DSM’s innovative, biocompatible drug carrier changes the way active compounds are delivered locally to the body via unique enzyme-mediated bioerosion. Svelte and DSM have been working under a joint collaboration and development agreement since November 2010 and execution of this agreement further validates the innovative properties of DSM’s polyesteramide (PEA) biomaterials and the potential of DSM’s drug delivery technology.

“Our coronary stent platform currently provides the lowest profile and most deliverable balloon expandable coronary stent technology in the market. By collaborating with DSM, we can expand our technology platform and introduce our much anticipated second generation product. The combination of DSM’s drug delivery technology and the well-established sirolimus drug has the potential to improve patient safety and minimize the need for dual anti-platelet therapy,” said Mark Pomeranz, President and CEO at Svelte Medical Systems, Inc.

“Our proprietary bioerodible drug carrier is suitable to deliver a range of active pharmaceutical agents including preventative blood clotting agents, immunosuppressants and a variety of other drugs, while degrading in controlled, biocompatible, natural and nontoxic fashion. This drug carrier markedly improves the way active compounds are delivered from stent systems,” said Donato DiBiase, Global Business Director, Drug Delivery, DSM Biomedical.

“DSM’s ability to create groundbreaking drug carriers offering innovative applications to improve the efficacy of medical devices and clinical outcomes for patients continues to differentiate us in the biomaterials space,” said Christophe Dardel, President of DSM Biomedical. “As the drug delivery market continues to be a strategic focus for DSM, we are thrilled to be working with Svelte Medical Systems as they expand their interventional cardiology technology platform.”

This announcement precedes the start of TCT in San Francisco, CA, where Svelte Medical’s first generation All-in-One stent system will be featured.

DSM – Bright Science. Brighter Living.™

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

About Svelte® Medical Systems, Inc.

Svelte® Medical Systems is a privately held company developing highly deliverable balloon expandable stents with a focus on reducing time and cost in angioplasty procedures. The company’s “All-In-One” coronary stent system is a low profile, highly flexible stent system which navigates the vasculature in a fashion similar to a traditional guidewire. The unique design allows physicians to eliminate several steps in the stenting procedure whencompared to currently marketed systems and reduces the need for ancillary devices, resulting in potential cost savings. The company has also developed a drug eluting version of their “All-in-One” system. More information can be found at: http://www.sveltemedical.com/


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
The role of exercise-induced hormone irisin in amyloid beta reduction